2(1H)-Pyridinimine Derivatives for α-Synuclein Aggregate Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's disease lack effective methods to suppress or reduce the accumulation of α-synuclein aggregates in the brain, and there is a lack of in vitro evaluation systems to assess the efficacy of potential therapeutic agents.
Innovation Solution
A 2(1H)-pyridinimine derivative or its pharmaceutically acceptable salt, which can suppress or reduce the accumulation of abnormal protein aggregates in the brain, and a method for reproducing Parkinson's disease pathology using neurospheroids to evaluate the amount of α-synuclein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Parkinson's disease are used, then symptomatic relief is provided, but the accumulation of α-synuclein aggregates is not suppressed or reduced
Solution Approach 1:
The patent introduces a novel 2(1H)-pyridinimine derivative as an intermediary substance that mediates between the body's natural processes and the pathological α-synuclein aggregates. This compound acts as a selective inhibitor that binds to and suppresses the aggregation of α-synuclein without interfering with normal physiological functions, thereby providing fundamental disease modification rather than just symptomatic relief
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of the 2(1H)-pyridinimine derivative through systematic variation of substituents (R1-R6 groups) to optimize its ability to suppress α-synuclein aggregation. By adjusting molecular parameters such as hydrophobicity, steric bulk, and electronic properties, the compound achieves high selectivity and potency in preventing aggregate formation while maintaining safety
2Productivity
If in vitro evaluation systems are used to assess potential therapeutic agents, then drug screening is enabled, but accurate evaluation of α-synuclein aggregate suppression is not possible
Solution Approach 1:
The patent creates a self-service evaluation system where the neurospheroid model inherently provides its own readout for aggregate formation. The three-dimensional cultured neurons automatically produce α-synuclein aggregates under controlled conditions, and the extent of aggregation can be directly measured as an indicator of both disease pathology and drug efficacy, eliminating the need for complex external evaluation systems
Solution Approach 2:
The patent extracts the essential pathological feature of Parkinson's disease (α-synuclein aggregation) from the complex in vivo system and isolates it in a simplified in vitro neurospheroid model. This extraction allows for focused, accurate measurement of aggregate suppression activity while maintaining the biological relevance of neuronal cells, providing a precise evaluation platform for drug screening
Data Source
AI summary
The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., X is oxygen, etc., Y is carbon, etc., Z is C1-6 alkyl, etc., m and n are an integer of 0, 1, 2, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.